Why would anyone want to own MYL in the next year or so (unless you think they will get FDA approval for generic Copaxone)?
After the ‘spinversion’ (#msg-107440341), ABT will own 22% of MYL and plans to divest its MYL shares fairly quickly, which will put a lot of pressure on MYL’s share price.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”